Innovent Biologics May See Stronger Commercial Outlook -- Market Talk

Dow Jones

Jul 08

0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

July 08, 2025 00:56 ET (04:56 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2549959430"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549959430\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549959430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 12:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549959430","market":"sh","top_or_hot":-1,"title":"Innovent Biologics May See Stronger Commercial Outlook -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0456 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&amp;D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 00:56 ET (04:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent Biologics May See Stronger Commercial Outlook -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent Biologics May See Stronger Commercial Outlook -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-08 12:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0456 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a> will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, <a href=\"https://laohu8.com/S/HSBC\">HSBC</a> Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&amp;D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2025 00:56 ET (04:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1572","symbol_name":"香港银行股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2549959430","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549959430","pubTimestamp":1751950560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1572":"香港银行股","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","BK1589":"北水核心资产","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","BK4588":"碎股","HSBA.UK":"汇丰控股有限公司","HSHD.SI":"HSBC HK SDR 5to1","BK1231":"综合性银行","00005":"汇丰控股","BK4207":"综合性银行","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK1610":"ETF&股票定投概念","BK1161":"生物科技","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","BK4585":"ETF&股票定投概念","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","BK1601":"香港本地股","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK1583":"高瓴概念","HSBC":"汇丰","01801":"信达生物","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","BK4521":"英国银行股","03143":"华夏香港银行股","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC"},"translate_title":"信达生物可能会看到更强劲的商业前景——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00005":0.9,"01801":0.9,"03143":0.6,"HSBA.UK":0.6,"HSBC":0.6,"HSHD.SI":0.6},"content_text":"0456 GMT - Innovent Biologics will likely see stronger commercial outlook for its PD1/IL2 assets and relevant business development potential, HSBC Global Research analysts write in a note. The company's solid anti-tumor efficacy data release and long-term sustainable growth potential from a robust early-stage pipeline and strengthened R&D capabilities are also promising, they say. The bank raised its earnings estimates for 2026 to 2027 by 10% to 58%, supported by the potential launch of PD1/IL2 and CLDN18.2 ADCs in domestic markets from 2027 per HSBC's forecast. The company is still attractively valued and there should be multiple catalysts ahead as upsides. HSBC Global Research maintains a buy rating for the stock and raises its target price to HK$110.00 from HK$65.80. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2025 00:56 ET (04:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}